Loading…
← CockpitCompetitor Analysis › 6945.TWO AP Biosciences, Inc.Open in the cockpit ↗

AP Biosciences, Inc.6945.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum strong 71
Mkt cap
$321M
US dollars, full cap
$/day
$1.06M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-22.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · TWDNT$120.00
1D-2.4%
1W+2.1%
1M-1.6%
3M+14.8%
6M-31.4%
YTD-33.3%
1Y+4.8%
ATR %7.0%
52w lowhigh49.1% off high

What AP Biosciences does

Employees: 43

AP Biosciences at a glance

Size AP Biosciences (6945.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $321M, the 615th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$120.00 on 18 Nov 2026.

Performance Over six months the shares fell 31.4%, against -24.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 8th lowest of 20 in its peer set.

Capital Return on invested capital runs 22.1 points below its cost of capital (5.0% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 706945.TWO 68
Six months, rebased to 100: AP Biosciences against the median of its 20 peers (local-currency closes).

AP Biosciences financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$0NT$0NT$0NT$32.3MNT$0
Revenue growth——-100%——
Gross profitNT$0-NT$25.5M-NT$17.5Mn/a-NT$8.68M
EBITDAn/a-NT$431M-NT$422M-NT$335M-NT$289M
Net income-NT$397M-NT$445M-NT$423M-NT$339M-NT$289M
Free cash flown/a-NT$377M-NT$363M-NT$333M-NT$277M
Capital expendituren/aNT$25.3MNT$5.53MNT$35.4MNT$2.43M
Total debtn/aNT$59.5MNT$70.9MNT$82.1MNT$0

Quarterly statements and history in the cockpit →

AP Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%7630CCCC2105PROK3880NAUT4894LRMRXFOR358570LYELGLSIGALT086900CRMDCTNM4760603003816945.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. AP Biosciences is the large dot.

AP Biosciences competitors and peer comparison

How AP Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

AP Biosciences against its 20 peers (data as of 18 Nov 2026)
Measure6945.TWOPeer medianRank in peer set
1-month return-1.6%-5.7%7th highest of 20
6-month return-31.4%-24.7%8th lowest of 20
Distance from 52-week high-49.1%-54.6%7th highest of 20
ROIC minus cost of capital-22.1 pp-63.8 pp7th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are AP Biosciences's closest peers?
The cockpit's peer set: IMPACT Therapeutics (7630.HK), C4 Therapeutics (CCCC), Laekna (2105.HK), ProKidney (PROK), Medtide (3880.HK), Nautilus Biotechnolgy (NAUT), Cuorips (4894.T), Larimar Therapeutics (LRMR).
How has AP Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -31.4% against -24.7% for the median peer; over one year +4.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.